tgAAV-CF gene therapy - Targeted Genetics

Drug Profile

tgAAV-CF gene therapy - Targeted Genetics

Alternative Names: tgAAV2-CF; tgAAVCF

Latest Information Update: 01 May 2007

Price : $50

At a glance

  • Originator Targeted Genetics Corporation
  • Class Gene therapies
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 16 Mar 2005 Data from a media release have been added to the Respiratory Tract Disorders therapeutic trials section
  • 16 Mar 2005 Discontinued - Phase-II for Cystic fibrosis in USA (Inhalation)
  • 16 Mar 2005 Discontinued - Phase-II for Cystic fibrosis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top